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Abstract
Purpose We examined p16, p21 and p53 expression in
combination with the presence of human papillomavirus
(HPV) DNA as molecular markers to predict survival in
patients with stage IV hypopharyngeal squamous cell carci-
noma (HSCC).
Methods ParaYn-embedded tumours from HSCC
patients (n = 75) were evaluated for p16, p21 and p53
expression by immunohistochemistry. HPV DNA was
detected by GP5+/6+ consensus PCR and subsequent geno-
typing by E6/E7 type-speciWc PCR for HPV types 6, 11,
16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68.
Results Among the 61 specimens that tested positive for
the -globin, HPV typing identiWed 50 patients with high-
risk (hr) HPV types. HPV 16E7 DNA was detected in 74%
(37 cases) of these specimens. Twelve patients were found
to be infected with multiple HPV types. However, the pres-
ence of hrHPV DNA was not found to correlate with the
proportion of disease-free patients. The 5-year disease-free
survival rate was 73% in p53¡ tumours versus 48% in
p53+ tumours (P = 0.008).
Conclusion In our series of patients with stage IV HSCC,
the hrHPV+ subgroup had a similar prognosis (in terms of
recurrence risk) as the HPV¡ subgroup. p53 overexpres-
sion was associated with a worse prognosis.
Keywords Human papillomavirus · PCR · Typing · 
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Introduction
Head and neck squamous cell carcinoma (HNSCC)
represents the sixth most common form of cancer that is
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diagnosed worldwide. It is the most common malignant
neoplasm that arises from the mucosa of the upper aerodi-
gestive tract (Grandis et al. 2004; Hunter et al. 2005). Dur-
ing the past 30 years, survival rates have not improved
signiWcantly for this type of cancer, and 50% of HNSCC
patients still eventually die of their disease and 5% develop
additional primary tumours each year (Grandis et al. 2004;
Hunter et al. 2005). Furthermore, HNSCC has a large
impact on the quality of life of all HNSCC patients and sur-
vivors (Bernier et al. 2004; Cooper et al. 2004). SigniWcant
morbidity caused by the treatments often mandates long-
term multidisciplinary care, which leads to increased Wnan-
cial burdens for institutions that treat HNSCC patients
(Hunter et al. 2005). The management of head and neck
cancer has become increasingly complex in recent years
due to combined-modality treatment regimens as well as
the integration of new diagnostic and therapeutic technolo-
gies. Nearly two-thirds of HNSCC patients present with
advanced disease (stages III and IV). Despite the use of
resection and concomitant post-operative chemotherapy
and radiotherapy, these advanced HNSCCs frequently recur
in the original tumour beds (Hunter et al. 2005; Schantz
et al. 1997). Patients with stage IV hypopharyngeal carci-
noma represent one of the HNSCC subgroups with the
worst prognosis, as the 5-year survival rate for this popula-
tion is less than 15%.
Biological markers are therefore required to identify the
high-risk HNSCC patients who are in need of highly
aggressive treatments after surgical resection of their
tumours (Grandis et al. 2004). Over the last 10 years, it has
become clear that there is a subset of oropharyngeal squa-
mous cell carcinomas (OSCCs) that is associated with high-
risk human papillomavirus (hrHPV) infection, in particular
HPV type 16 (D’Souza et al. 2007). HPV-positive OSCCs
seem to be diVerent from HPV-negative tumours with
respect to tumour diVerentiation, risk factors and the
genetic changes that are present, indicating that HPV-
positive OSCCs represent a separate tumour entity from
HPV-negative OSCCs, which have speciWc molecular path-
ways associated with their tumourigenicity (Reimers et al.
2007). A recent case–control study comparing 100 patients
with OSCC and 200 control patients demonstrated that oral
HPV infection was strongly associated with oropharyngeal
carcinoma among patients who did not have the classical
risk factors of tobacco and alcohol use (D’Souza et al.
2007). This study also demonstrated that a high lifetime
number of oral sex or vaginal sex partners, engagement in
casual sex, early age at Wrst intercourse and infrequent use
of condoms were all associated with HPV-16-positive oro-
pharyngeal cancer (D’Souza et al. 2007).
Molecular studies of cervical carcinoma, the cancer
that has the most widely accepted association with HPV,
have shown that after integration of the virus, the
expression of the transcription factor E2 (which represses
the transcription of E6 and E7 oncogenes) is disrupted. As
a consequence of this disruption, the E6 and E7 genes are
transcribe and result in the production of oncoproteins
that bind to and degrade the p53 and retinoblastoma (Rb)
tumour suppressor, respectively. The p16 protein func-
tions as a tumour suppressor by binding to the cyclin D1
CDK4/CDK6 complex, thereby preventing phosphoryla-
tion of the Rb protein. Rb downregulation subsequently
results in p16 upregulation (Weinberger et al. 2006).
Begum et al. (2003) have shown that p16 overexpression
is a marker of oropharyngeal origin and has association
with HPV infection in HNSCC tumours. In contrast, in
tobacco-related HNSCCs, the loss of the tumour-suppressor
p16 protein is a common and early event in tumourigene-
sis (Reed et al. 1996). Several studies that were dedicated
to studying oral and oropharyngeal carcinomas have dem-
onstrated that HPV-positive patients have a better progno-
sis than HPV-negative patients (Ritchie et al. 2003;
Weinberger et al. 2006). A more recent study showed that
HPV-16 copy number was positively associated with
response to concomitant chemoradiotherapy and with bet-
ter overall and disease-speciWc survival (Kumar et al.
2007). Moreover, joint assessment of p53 expression and
HPV infection seems to provide an excellent indicator of
prognosis (Smith et al. 2008). In a large series of 294
HNSCCs with 10 years of follow-up, Smith et al. (2008)
observed that patients with tumours that were p53¡/
hrHPV+ had the highest survival and lowest recurrence
rates, whereas patients with tumours that were p53+/
HPV¡ had signiWcantly worse outcomes.
Despite their promise as prognostic markers for patients
with OSCC, no studies have been performed to analyse the
prognostic implication of this combination of markers in
patients with hypopharyngeal carcinoma. In the current
study, we examined the clinical utility of the combination
of the most promising predictive markers for OSCC,
including HPV DNA detection as well as p16, p21 and p53
expression in a homogeneous series of 75 patients with
stage IV hypopharyngeal SCC.
Materials and methods
Histopathological and clinical data
Formalin-Wxed, paraYn-embedded hypopharyngeal squa-
mous cell carcinoma (HSCC) tumour specimens were
obtained from 4 female and 71 male patients who under-
went radical curative-intent surgery between January 1996
and December 2000 in the E.N.T. Department of the Hôpi-
tal Claude Huriez (Lille, France). For each surgical speci-
mens, we have selected the paraYn block presenting theJ Cancer Res Clin Oncol (2011) 137:173–181 175
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higher proportion of carcinoma (avoiding necrotic area fre-
quently observed in the central part of the tumour). Clinical
staging was performed according to the TNM classiWcation
system (Wittekind et al. 2004), and data regarding the
tumours of the 75 stage IV hypopharyngeal patients
included in this study are detailed in Table 1. The diagnoses
were established based on the histological criteria previ-
ously described by Hyams et al. (1988). All hypopharyn-
geal SCCs included in this study were primary tumours,
and the patients did not have distant metastases or recur-
rences. The tumours were categorised as well-diVerentiated
(n = 38), moderately diVerentiated (n = 26) and poorly
diVerentiated (n = 11). This retrospective study was
approved by the local Institutional Review Board.
All of the hypopharyngeal SCC specimens used in this
study came from patients who did not undergo chemother-
apy and/or radiotherapy before surgery. After surgery, all
patients were treated with standard post-operative radio-
therapy, but not chemotherapy. All patients used alcohol
and tobacco. Thus, the 75 stage IV hypopharyngeal SCC
specimens that were included in this study comprised a
very homogeneous sample, both clinically and histopatho-
logically.
DNA extraction
The formalin-Wxed, paraYn-embedded tissue samples were
sectioned (10 £ 5 m), deparaYnised and digested with
proteinase K by overnight incubation at 56°C. DNA was
puriWed using the QIAamp DNA Mini Kit (Qiagen, Bene-
lux, Belgium) according to the protocol recommended by
the manufacturer.
Detection of HPV by polymerase chain reaction (PCR) 
ampliWcation
HPV detection was performed by PCR using GP5+/GP6+
primers (synthesised by Eurogentec, Liege, Belgium).
These GP5+/GP6+ primers amplify a consensus region
located within L1 region of the HPV genome. PCR for
HPV-L1 DNA ampliWcation was performed in 25 l of a
reaction mixture containing 2 l of extracted DNA, 2.5 l
1 £ PCR buVer, 0.025 U Taq DNA polymerase (Roche,
Mannheim, Germany), 200 M dNTPs and 0.5 pmol of
each primer. The cycling conditions for PCR were as fol-
lows: denaturation was performed at 94°C for 1 min,
annealing was performed at 40°C for 1 min 30 s and exten-
sion was performed at 72°C for 2 min for a total of 40
ampliWcation cycles. The Wrst cycle was preceded by a
3-min denaturation step at 94°C. The last cycle was followed
by an additional 5-min extension step at 72°C. Aliquots
(10 l) of each PCR product were electrophoresed through
a 1.8% agarose gel and stained with ethidium bromide to
allow for visualisation of the ampliWed HPV-L1 DNA
fragments.
Real-time quantitative PCR ampliWcation of type-speciWc 
HPV DNA
All DNA extracts were tested for the presence of 18 diVer-
ent HPV genotypes using TaqMan-based real-time quanti-
tative PCR targeting type-speciWc sequences of the
following viral genes: 6 E6, 11 E6, 16 E7, 18 E7, 31 E6, 33
Table 1 Patient characteristics
Mean age: 55 years (range 40–78)
Gender
Male: 71 patients (95%)
Female: 4 patients (5%)
Localisation
Piriform sinus: 56 cases (75%)
Postcricoid area: 16 cases (21%)
Posterior wall: 3 cases (4%)
Grade
Well diVerentiated: 38 cases (51%)
Moderately diVerentiated: 26 cases (34%)
Poorly diVerentiated: 11 cases (15%)
TNM stage: (n = 75 cases of stage IV disease)
T2N2: 8 cases
T3N2: 7 cases
T4N0: 12 cases
T4N1: 6 cases
T4N2: 39 cases
T4N3: 3 cases
Treatment
Partial pharyngolaryngectomy: 9 cases
Total pharyngolaryngectomy: 49 cases
Circular pharyngolaryngectomy: 8 cases
Esopharyngolaryngectomy: 9 cases
28 presented larynx cartilage invasion
112 neck dissections in 75 patients
47 patients with extranodal spread
All patients were treated with standard post-operative 
radiotherapy, but did not receive post-operative chemotherapy.
Recurrence: (n =2 3 )
Local recurrence: 17 cases
Distant recurrence: 11 cases
Follow-up: (72 patients had clinical follow-up data available)
9 second primary cancers: 6 cases of lung cancer, 
1 case of prostate cancer, 1 case of kidney cancer
6 head and neck second primaries
29 deaths, including 20 caused by the HNSCC and 9 deaths that 
were unrelated to HNSCC (5 caused by a second primary cancer, 
3 caused by medical disease, and 1 from unknown causes)176 J Cancer Res Clin Oncol (2011) 137:173–181
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E6, 35 E6, 39 E7, 45 E7, 51 E6, 52 E7, 53 E6, 56 E7, 58
E6, 59 E7, 66 E6, 67 L1 and 68 E7 (Depuydt et al. 2006).
For the diVerent real-time quantitative PCR assays, the ana-
lytical sensitivity ranged from 1 to 100 copies and was cal-
culated using standard curves for 18 type-speciWc PCRs
constructed with plasmids containing the entire genome of
the diVerent HPV types (Depuydt et al. 2007). Real-time
quantitative PCR for the detection of -globin was per-
formed in each PCR assay to verify the quality of the DNA
in the samples and to measure the amount of input DNA
(Arbyn et al. 2009; Depuydt et al. 2007).
The following HPV types that were tested were consid-
ered to be high-risk (hr): 16, 18, 31, 33, 35, 39, 45, 51, 52,
53, 56, 58, 59 and 66.
Immunohistochemistry
All tumour samples were Wxed in 10% buVered formalde-
hyde for 24 h, dehydrated and embedded in paraYn. Immu-
nohistochemistry was performed on 5-m-thick sections
mounted on silane-coated glass slides (Saussez et al. 2008).
Before starting the immunohistochemistry protocol, depar-
aYnised tissue sections were placed in a 0.01 M citrate
buVer (pH 6.0) and brieXy pre-treated in a microwave for
2 £ 5 min at 900 W. The sections were then incubated with
a solution of 0.4% hydrogen peroxide for 5 min to block
endogenous peroxidase activity, rinsed in phosphate-
buVered saline (PBS; 0.04 M Na2HPO4, 0.01 M KH2PO4
and 0.12 M NaCl, pH 7.4) and successively exposed to
solutions containing avidin (0.1 mg/ml in PBS) and biotin
(0.1 mg/ml in PBS) for 20-min periods to avoid false-
positive staining reactions resulting from the presence of
endogenous biotin. After a thorough washing with PBS, the
sections were incubated for 20 min with a solution of 0.5%
casein in PBS and sequentially exposed to the following
solutions: (1) the speciWc primary antibody; (2) the corre-
sponding biotinylated secondary antibody (polyclonal goat
anti-rabbit IgG); (3) the avidin–biotin-peroxidase complex
(ABC kit), all at room temperature. The samples were sub-
jected to thorough washing steps to remove unbound pro-
teins in between incubation steps. The antigen-dependent
presence of the peroxidase complex in the sections was vis-
ualised by incubation with the chromogenic substrates con-
taining diaminobenzidine and H2O2. After rinsing, the
sections were counterstained with luxol fast blue and
mounted in a synthetic medium. To exclude antigen-
independent staining, the incubation step with primary/sec-
ondary antibodies was omitted from the protocol in control
samples. In all instances, these controls were negative. The
biotinylated secondary antibodies and ABC kit were
obtained from DakoCytomation (Glostrup, Denmark). The
p16, p21 and p53 antibodies came, respectively, from Abcam
(for p16 and p21, Cambridge, UK) and DakoCytomation
(Glostrup, Denmark). Assessment of p16, p21 and p53
immunoreactivities was performed by two investigators
who were blinded to the clinical details of the patients.
Tumours were classiWed in a binary manner as either
p16-, p21- and p53-positive (strong, diVuse staining) or
p16-, p21- and p53-negative (weak or absent staining; i.e.,
the labelling index (LI) corresponding to the percentage of
immunopositive cells was ·5%).
Data analysis
Categorical data from independent groups were compared
using the chi-square test or Fisher’s exact test as appropri-
ate. Survival was measured in months from the date of
diagnosis until death or until the date at which patient was
last known to be alive. The standard survival time analyses
were performed using Kaplan–Meier curves and the Gehan
generalised Wilcoxon and log-rank tests. The statistical
analyses were performed using the Statistica software pack-
age (Statsoft, Tulsa, USA).
Results
HPV status as determined by the GP5+/GP6+ consensus 
primer and by real-time quantitative PCR ampliWcation of 
type-speciWc HPV DNA and correlation with 
clinicopathological parameters
A total of eight cases of the 75 specimens were found to
have insuYcient tissue quantities available for DNA extrac-
tion or quantitative PCR after pathological evaluation and
immunohistochemistry and were therefore excluded from
further analysis (Fig. 1). Out of the remaining 67 cases,
another six cases, which were -globin PCR-negative, were
also excluded from further analysis. Ultimately, 61 -globin
PCR-positive specimens were typed using quantitative
real-time PCR using primers for 18 diVerent HPV types
(Fig. 1). From this homogenous group of 61 HSCC tumour
specimens, we identiWed 50 patients (82%) whose tumours
tested positive for the following hrHPV types: HPV 16 (37
cases), 18 (4 cases), 33 (11 cases), 39 (1 case), 51 (5 cases),
53 (1 case), 58 (2 cases), 59 (1 case) and 66 (4 cases).
Twelve patients were infected with multiple types of
hrHPV. In the hrHPV¡ negative subgroup (n = 11), four
patients tested positive for HPV infection using the GP5+/
GP6+ consensus primers and were considered to be
infected with low-risk (lr) HPV types (Fig. 1). Only seven
tumours were negative for both GP5+/GP6+ and type-
speciWc HPV PCR analysis (11%). Among the 50 patients
with hrHPV+ tumours, 38 tumours were both GP5+/GP6+-
positive and type-speciWc HPV-positive (hrHPV+ group).
However, 12 tumours were GP5+/GP6+-negative andJ Cancer Res Clin Oncol (2011) 137:173–181 177
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type-speciWc HPV-positive, corresponding to an integrated
HPV+ group (int. hrHPV+) (Fig. 1).
The mean age and the sex ratio of the patients with hrHPV+
tumours (50 cases) were both identical to those of the patients
with HPV- or lrHPV+ tumours (11 cases). Statistical analysis
did not reveal a signiWcant correlation between hrHPV positiv-
ity (as determined by E6/E7 real-time quantitative PCR ampli-
Wcation), and the percentage of tumours that were poorly
diVerentiated or had lymph node involvement, capsular eVrac-
tion or laryngeal cartilage invasion (Table 2). The hrHPV posi-
tivity was not found to be correlated with the proportion of
disease-free patients in our series of patients with stage IV
hypopharyngeal carcinoma (Fig. 2). However, 32% (16/50
cases) of patients with hrHPV+ tumours recurred, when com-
pared to 8% of patients with HPV¡ or lrHPV+ tumours. The
5-year disease-free survival was 88% in HPV¡ or lrHPV+
tumours versus 58% in hrHPV+ tumours (log-rank test, NS).
p16 expression as determined by immunohistochemistry 
(IHC)
Immunohistochemical expression of p16 was detected in 7
(9%) out of 75 tumours (Fig. 3a,b,c). As visualised in
Fig. 3b, p16 displayed a diVuse cytoplasmic/nuclear pattern
of expression that was dichotomous [highly expressed
(Fig. 3b)  versus low/no expression (Fig. 3a)]. When all
tumours that expressed p16 (7 cases) were compared to
those that did not (68 cases), p16 positivity was found to
correlate with a better prognosis. In fact, all patients whose
tumours expressed p16 were free of disease (Fig. 3c). The
5-year disease-free survival rate was 100% in p16+
tumours  versus 58% in p16¡ tumours (P =N S ) .  T h i s
diVerence was not statistically signiWcant, probably due to
the small size of the p16+ group (log-rank test: NS). All
hrHPV+ patients’ tumours expressed p16 (Table 2).
p21 expression as determined by IHC
Immunohistochemical expression of p21 was detected in
84% of HSCC specimens (Fig. 4). Moderate-to-intense
brown nuclear staining was considered to be a positive
result (Fig. 4). The 5-year disease-free survival rate was
60% in p21+ tumours versus 70% in p21¡ tumours. The
proportion of disease-free patients was not signiWcantly
diVerent between the p21+ and p21¡ groups (Fig. 4c).
Similar rates of p21 positivity were observed in the
Fig. 1 Flow diagram of the pro-
cessing and HPV PCR results 
from formalin-Wxed, paraYn-
embedded hypopharyngeal car-
cinoma specimens included in 
this study. Archived tissue 
blocks were obtained from 75 
patients who underwent cura-
tive-intent surgery for stage IV 
hypopharyngeal carcinoma 
between January 1996 and 
December 2000. Eight samples 
could not be analysed due to 
insuYcient material, and in 
another six samples, -globin 
could not be ampliWed. There-
fore, 61 cases were analysed by 
type-speciWc real-time PCR. 
Among these patients, 82% test-
ed positive for infection with one 
or several types of hrHPVs, 7% 
were positive for lrHPV and 
11% were HPV¡. Among the 50 
patients with hrHPV+ tumours, 
38 tumours were both GP5+/
GP6+-positive and type-speciWc 
HPV-positive (hrHPV+ group). 
However, 12 tumours were 
GP5+/GP6+-negative and 
type-speciWc HPV-positive, 
corresponding to an integrated 
HPV+ group (int. hrHPV+)178 J Cancer Res Clin Oncol (2011) 137:173–181
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hrHPV+ tumour group (79.5% were p21 +) and in the
HPV¡ or lrHPV+ tumour group (82% were p21+)
(Table 2).
p53 expression as determined by IHC
Due to insuYcient biopsy material, two cases could not be
analysed for p53 expression. Overexpression of p53 was
detected in 27 of the 73 (37%) hypopharyngeal SCC
samples that were analysed (Fig. 5). In the HPV¡ group,
36% of tumours (4/11) were found to overexpress p53,
whereas 33% of tumours in the hrHPV+ group (16/48
cases) were found to overexpress p53 (Fisher’s exact test,
NS) (Table 2). As shown in Fig. 5b, p53 expression was
assessed by the presence of typical nuclear staining. Sur-
vival analysis showed that p53 overexpression was signiW-
cantly associated with worse prognosis in our homogenous
series of stage IV hypopharyngeal SCC patients (Fig. 5c).
The 5-year disease-free survival was 73% in p53¡ tumours
versus 48% in p53+ tumours (log-rank test, P = 0.008).
We carried out multivariate Cox regression models on
clinical and biological variables (age, node status, capsular
eVraction, QPCR-PCR HPV, p16, p21, p53 expression).
These analyses conWrmed univariate results, i.e. only p53
brought signiWcant contribution to prognosis. No other clin-
ical or biological variable was able to signiWcantly contrib-
ute to the model (data not shown).
Discussion
Epidemiological, molecular and clinical evidence indicate
that hrHPV may play a pivotal role in the development of
HNSCCs. However, most previous studies on this topic
Table 2 Correlation between HPV status and the percentage of
patients with lymph node involvement, capsular eVraction or cartilage
inWltration as well as p16, p21 and p53 expression
NS not signiWcant
hrHPV+ versus HPV¡ or lrHPV+:
p: NS Lymph node 
involvement: N0
Lymph node 
involvement: N+
hrHPV+ 11/50 (22%) 39/50 (78%)
HPV¡ or lrHPV+ 1/11 (9%) 10/11 (91%)
p: NS Capsular eVraction: 
No
Capsular eVraction: 
yes
hrHPV+ 18/48 (37.5%) 30/48 (62.5%)
HPV¡ or lrHPV+ 4/11 (36%) 7/11 (64%)
p: NS Cartilage invasion: 
No
Cartilage invasion: 
yes
hrHPV+ 32/49 (65%) 17/49 (35%)
HPV¡ or lrHPV+ 4/11 (36%) 7/11 (64%)
p: NS p 16+ p 16¡
hrHPV+ 5/46 (11%) 41/46 (89%)
HPV¡ or lrHPV+ 0/10 (0%) 10/10 (100%)
p: NS p 21+ p 21¡
hrHPV+ 35/44 (79.5%) 9/44 (20.5%)
HPV¡ or lrHPV+ 9/11 (82%) 2/11 (18%)
p: NS p 53+ p 53¡
hrHPV+ 16/48 (33%) 32/48 (67%)
HPV¡ or lrHPV+ 4/11 (36%) 7/11 (64%)
Fig. 2 Disease-free survival curves for high-risk HPV+ (hrHPV+)
versus HPV¡ and low-risk HPV+ (lrHPV+) patients. The P-value is
not signiWcant (NS)
Fig. 3 Typical p16 immunohistochemical staining proWle for stage IV
hypopharyngeal carcinomas (a: p16 non-expressor and b: p16 expres-
sor). c shows the survival curves for p16-expressor versus p16-non-
expressor patients. The P-value is not signiWcant (NS). MagniWcation
a–b £320J Cancer Res Clin Oncol (2011) 137:173–181 179
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have focused on OSCCs (Dahlstrand et al. 2008). D’Souza
et al. (2007) showed that oral HPV infection was signiW-
cantly associated with OSCC among patients with or with-
out a history of tobacco and alcohol use. In a Swedish
study, oral hrHPV infection was associated with dramati-
cally increased risk of OSCC development (odds ratio 230)
after adjusting for alcohol and tobacco consumption
(Hansson et al. 2005). Several studies have suggested that
oral HPV infection is sexually acquired (D’Souza et al.
2007; Hansson et al. 2005). However, even though oral-
genital contact may be implicated in oral HPV transmis-
sion, transmission through direct mouth to mouth contact or
other means could not be excluded (Saussez et al. 2008).
Tonsillar crypts, which have an oropharyngeal sublocation
that is histologically similar to the transformation zone of
the uterine cervix, seem to be particularly susceptible to
HPV-induced malignant transformation (D’Souza et al.
2007; Hansson et al. 2005; Psyrri and DiMaio 2008). HPV-
associated carcinomas tend to be poorly diVerentiated, and
HPV-16 is the most prevalent genotype that is present in
this type of tumour. Moreover, other studies have demon-
strated that patients with hrHPV+ OSCC have a better
prognosis than hrHPV¡ OSCC patients and that speciWc
subgroups of hrHPVs+ tumours (speciWcally, those that
have certain molecular proWles, such as p16 overexpression
or p53 underexpression) were associated with better dis-
ease-free survival rates (Reimers et al. 2007; Ritchie et al.
2003; Smith et al. 2008; Weinberger et al. 2006). Several
studies have also demonstrated the involvement of HPV
infections in laryngeal and sino-nasal tumours (Aaltonen
et al. 2002; Alos et al. 2009). Very few publications have
focused on HPV positivity in hypopharyngeal cancers. Our
results revealed that a large percentage (82%) of the tumour
specimens that we studied were hrHPV+. These Wndings
are in accordance with a previous study by Morgan et al.
(1991) who described for the Wrst time that 75% of the 16
pharyngolaryngeal carcinomas in their series were HPV+.
Another study found a lower HPV positivity rate (46%) in
the tumours of 78 previously untreated patients with laryn-
geal and hypopharyngeal carcinomas (Clayman et al.
1994). The authors concluded that HPV+ tumours repre-
sented a biologically distinct subset of tumours that had a
worse prognosis than HPV¡ tumours (Clayman et al.
1994). In contrast to our results, Paz et al. (1997) did not
identify any HPV+ tumours in a small series of 7 hypopha-
ryngeal carcinoma patients. This Wnding might be
explained by the fact that, in our study, we used a very sen-
sitive (10–100 copies per PCR reaction) and type-speciWc
real-time quantitative PCR analysis with a short ampliWca-
tion product (60–80 bp), which is less vulnerable to the
Fig. 4 Typical p21 immunohistochemical staining proWle for stage IV
hypopharyngeal carcinomas (a: p21 non-expressor and b: p21 expressor).
c shows the survival curves for p21-expressor versus p16-non-
expressor patients. The P-value is not signiWcant (NS). MagniWcation
a–b £320
Fig. 5 Typical p53 immunohistochemical staining proWle for stage IV
hypopharyngeal carcinomas (a: p53 non-expressor and b: p53
expressor). c shows the survival curves of p53-expressor versus
p53-non-expressor patients. MagniWcation a–b £320180 J Cancer Res Clin Oncol (2011) 137:173–181
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presence of degraded DNA in paraYn-embedded speci-
mens than some other analytical methods. We demon-
strated for the Wrst time in a large series of stage IV HSCC
patients that 82% of tumours had hrHPV DNA present.
Furthermore, a signiWcant number of patients (20%) were
infected with multiple types of hrHPV.
The signiWcance of hrHPV infection and its relationship
with patient prognosis is still an important matter of debate,
especially considering the contradictory results that are
present in diVerent studies in the literature (Dahlstrand
et al. 2008; Rosenquist et al. 2007). Several studies have
demonstrated that the presence of HPV DNA in tonsillar
carcinomas is a favourable prognostic factor with regard to
clinical outcomes (recurrence and survival) (Dahlstrand
et al. 2008). In contrast, a recent study by Rosenquist et al.
(2007) showed that among patients with oral and oropha-
ryngeal tumours, the hrHPV+ subgroup had a higher risk of
recurrence or development of second primary tumour, but
had a lower risk of death due to intercurrent disease, when
compared to the hrHPV¡ group. In the current study, we
were not able to Wnd a signiWcant correlation between
hrHPV positivity and clinical data (speciWcally, tumour
diVerentiation, lymph node involvement, capsular eVrac-
tion or laryngeal cartilage invasion). However, our hrHPV+
group had a higher recurrence rate (32%, 16/50 cases) than
the HPV¡ and lrHPV+ groups (8%, 1/11 cases). This Wnd-
ing suggests that hrHPV positivity may be associated with
an elevated risk of tumour recurrence.
The oncoprotein E6 targets p53 for ubiquitin-mediated
degradation, while E7 binds to and inactivates the protein
product of the tumour-suppressor gene Rb (Munger et al.
1989; ScheVner et al. 1990). The p16 tumour suppressor
gene is often upregulated in HPV-induced cancers because
it is negatively regulated by pRb (Hara et al. 1996). In con-
trast, loss of p16 protein expression is a common and early
event in the development of tobacco-related HNSCCs.
Thus, tobacco/alcohol-associated HNSCCs appear to be
associated with p16 downregulation and the TP53 gene
mutation that results in the accumulation of p53 (corre-
sponding to p53 overexpression) (Psyrri and DiMaio 2008).
Our results demonstrate that the biology of hypopharyngeal
SCCs is probably more complex than previously thought
and that their tumourigenesis could involve several diVer-
ent molecular pathways. Our results illustrate the typical
tobacco-related loss of p16 expression; only 11% of the
tumours in our case series, which were obtained from
patients who used tobacco and alcohol, expressed this pro-
tein. Thus, p16 overexpression seems to be associated with
an improved prognosis. We did not Wnd a statistical diVer-
ence between the survival curves of p16+ expressors and
non-expressors (seven p16-expressor patients did not suVer
recurrence). The results of our study show that hrHPV
tumours have higher recurrence rates if these tumours also
overexpress p53 (when compared to p53¡/HPV¡ tumours)
(Table 2). Therefore, our Wndings suggest that p53 status
plays a more signiWcant role in predicting recurrence than
hrHPV status. This Wnding was also recently described by
Smith et al. (2008) in a large series of 294 HNSCC patients.
The strengths of our study include that we had a rela-
tively large, very homogenous case series comprised of
patients with stage IV hypopharyngeal carcinoma with sim-
ilar tobacco and alcohol habits. We were also able to study
the both independent and combined eVects of p16, p21, p53
and HPV status with regard to clinical outcomes (recur-
rence and survival). Another strength of this study was that
we had very good follow-up; we had recurrence and sur-
vival data with a signiWcant follow-up period available for
96% of our patients. Finally, we emphasise that our hypo-
pharyngeal carcinoma series is composed of only resectable
stage IV (60/75 cases presented negative surgical margins)
hypopharyngeal carcinomas. This Wnding likely explains
the relatively good overall survival rates for stage IV hypo-
pharyngeal carcinoma that we observed among this patient
group.
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